| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8db21e1eda6e052fe9e015b1a33e6db8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-0468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0085 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5386 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68cec68cb59b6dae83c23b21f553a6e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb65452bd972d7f2d30172184ecd2cda |
| publicationDate |
2021-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021262675-A1 |
| titleOfInvention |
Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide |
| abstract |
The present invention relates to a liquid pharmaceutical formulation and a method for administering a pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) budesonide, olodaterol and tiotropium bromide; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) and a pharmacologically acceptable stabilizer, optionally including other pharmacologically acceptable additives. |
| priorityDate |
2020-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |